162 related articles for article (PubMed ID: 37231503)
21. Blocking the autocrine regulatory loop of Gankyrin/STAT3/CCL24/CCR3 impairs the progression and pazopanib resistance of clear cell renal cell carcinoma.
Wang C; Wang Y; Hong T; Cheng B; Gan S; Chen L; Zhang J; Zuo L; Li J; Cui X
Cell Death Dis; 2020 Feb; 11(2):117. PubMed ID: 32051393
[TBL] [Abstract][Full Text] [Related]
22. Silencing of the chemokine CXC receptor 4 (CXCR4) hampers cancer progression and increases cisplatin (DDP)-sensitivity in clear cell renal cell carcinoma (ccRCC).
Wang W; Gan Z; Liu Q; Yan S; Mulati R; Wang Y
Bioengineered; 2021 Dec; 12(1):2957-2969. PubMed ID: 34180759
[TBL] [Abstract][Full Text] [Related]
23. Genetic and metabolic hallmarks of clear cell renal cell carcinoma.
Sanchez DJ; Simon MC
Biochim Biophys Acta Rev Cancer; 2018 Aug; 1870(1):23-31. PubMed ID: 29959988
[TBL] [Abstract][Full Text] [Related]
24. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
[TBL] [Abstract][Full Text] [Related]
25. CBX4 transcriptionally suppresses KLF6 via interaction with HDAC1 to exert oncogenic activities in clear cell renal cell carcinoma.
Jiang N; Niu G; Pan YH; Pan W; Zhang MF; Zhang CZ; Shen H
EBioMedicine; 2020 Mar; 53():102692. PubMed ID: 32113161
[TBL] [Abstract][Full Text] [Related]
26. Patient-derived renal cell carcinoma organoids for personalized cancer therapy.
Li Z; Xu H; Yu L; Wang J; Meng Q; Mei H; Cai Z; Chen W; Huang W
Clin Transl Med; 2022 Jul; 12(7):e970. PubMed ID: 35802820
[TBL] [Abstract][Full Text] [Related]
27. A transgenic mouse expressing miR-210 in proximal tubule cells shows mitochondrial alteration: possible association of miR-210 with a shift in energy metabolism.
Nakada C; Hijiya N; Tsukamoto Y; Yano S; Kai T; Uchida T; Kimoto M; Takahashi M; Daa T; Matsuura K; Shin T; Mimata H; Moriyama M
J Pathol; 2020 May; 251(1):12-25. PubMed ID: 32073141
[TBL] [Abstract][Full Text] [Related]
28. VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling.
Sun J; Tang Q; Gao Y; Zhang W; Zhao Z; Yang F; Hu X; Zhang D; Wang Y; Zhang H; Song B; Zhang B; Wang H
J Exp Clin Cancer Res; 2020 Jun; 39(1):104. PubMed ID: 32513235
[TBL] [Abstract][Full Text] [Related]
29. NOX4 functions as a mitochondrial energetic sensor coupling cancer metabolic reprogramming to drug resistance.
Shanmugasundaram K; Nayak BK; Friedrichs WE; Kaushik D; Rodriguez R; Block K
Nat Commun; 2017 Oct; 8(1):997. PubMed ID: 29051480
[TBL] [Abstract][Full Text] [Related]
30. The lncRNA SNHG5-mediated miR-205-5p downregulation contributes to the progression of clear cell renal cell carcinoma by targeting ZEB1.
Xiang W; Lv L; Zhou G; Wu W; Yuan J; Zhang C; Jiang G
Cancer Med; 2020 Jun; 9(12):4251-4264. PubMed ID: 32281285
[TBL] [Abstract][Full Text] [Related]
31. Claudin-10 overexpression suppresses human clear cell renal cell carcinoma growth and metastasis by regulating ATP5O and causing mitochondrial dysfunction.
Yang W; Zhang K; Zhang Z; Zhou J; Li L; Xu Y; Qiu J; Cai L; Gong Y; Gong K
Int J Biol Sci; 2022; 18(6):2329-2344. PubMed ID: 35414767
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma.
Yan L; Ding B; Liu H; Zhang Y; Zeng J; Hu J; Yao W; Yu G; An R; Chen Z; Ye Z; Xing J; Xiao K; Wu L; Xu H
Theranostics; 2019; 9(26):8377-8391. PubMed ID: 31754403
[TBL] [Abstract][Full Text] [Related]
33. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
[TBL] [Abstract][Full Text] [Related]
34. Down-regulation of CD74 inhibits growth and invasion in clear cell renal cell carcinoma through HIF-1α pathway.
Ji SQ; Su XL; Cheng WL; Zhang HJ; Zhao YQ; Han ZX
Urol Oncol; 2014 Feb; 32(2):153-61. PubMed ID: 23273913
[TBL] [Abstract][Full Text] [Related]
35. Aurora-A/FOXO3A/SKP2 axis promotes tumor progression in clear cell renal cell carcinoma and dual-targeting Aurora-A/SKP2 shows synthetic lethality.
Li P; Chen T; Kuang P; Liu F; Li Z; Liu F; Wang Y; Zhang W; Cai X
Cell Death Dis; 2022 Jul; 13(7):606. PubMed ID: 35831273
[TBL] [Abstract][Full Text] [Related]
36. Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications.
Adelaiye R; Ciamporcero E; Miles KM; Sotomayor P; Bard J; Tsompana M; Conroy D; Shen L; Ramakrishnan S; Ku SY; Orillion A; Prey J; Fetterly G; Buck M; Chintala S; Bjarnason GA; Pili R
Mol Cancer Ther; 2015 Feb; 14(2):513-22. PubMed ID: 25519701
[TBL] [Abstract][Full Text] [Related]
37. Cyclovirobuxine inhibits the progression of clear cell renal cell carcinoma by suppressing the IGFBP3-AKT/STAT3/MAPK-Snail signalling pathway.
Liu Y; Lv H; Li X; Liu J; Chen S; Chen Y; Jin Y; An R; Yu S; Wang Z
Int J Biol Sci; 2021; 17(13):3522-3537. PubMed ID: 34512163
[TBL] [Abstract][Full Text] [Related]
38. Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma.
Sourbier C; Srivastava G; Ghosh MC; Ghosh S; Yang Y; Gupta G; Degraff W; Krishna MC; Mitchell JB; Rouault TA; Linehan WM
Oncotarget; 2012 Nov; 3(11):1472-82. PubMed ID: 23178531
[TBL] [Abstract][Full Text] [Related]
39. Activation and function of receptor tyrosine kinases in human clear cell renal cell carcinomas.
Zhang Q; Liu JH; Liu JL; Qi CT; Yan L; Chen Y; Yu Q
BMC Cancer; 2019 Nov; 19(1):1044. PubMed ID: 31690270
[TBL] [Abstract][Full Text] [Related]
40. Targeting renal cell carcinoma with a HIF-2 antagonist.
Chen W; Hill H; Christie A; Kim MS; Holloman E; Pavia-Jimenez A; Homayoun F; Ma Y; Patel N; Yell P; Hao G; Yousuf Q; Joyce A; Pedrosa I; Geiger H; Zhang H; Chang J; Gardner KH; Bruick RK; Reeves C; Hwang TH; Courtney K; Frenkel E; Sun X; Zojwalla N; Wong T; Rizzi JP; Wallace EM; Josey JA; Xie Y; Xie XJ; Kapur P; McKay RM; Brugarolas J
Nature; 2016 Nov; 539(7627):112-117. PubMed ID: 27595394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
